Navigation Links
Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
Date:5/11/2012

Barcelona, Spain: Using a concentrated, highly targeted dose of radiation to the breast has equally good results as irradiating the whole area, with no adverse effects on survival and a much better cosmetic outcome, Hungarian researchers have found. Reporting the ten-year results of a randomised trial, Professor Csaba Polgr, MD, Director of the Centre for Radiotherapy, National Institute of Oncology, Budapest, will tell the World Congress of Brachytherapy [1 & 2] today (Friday) that he believes that accelerated partial breast irradiation (APBI) could be offered to many more breast cancer patients, resulting in fewer side effects and major cost savings to healthcare systems.

The Budapest trial was the first randomised study to compare the efficacy and side effects of conventional whole breast irradiation with APBI using multicatheter brachytherapy. This technique consists of inserting multiple plastic catheters into the tumour bed after breast conserving surgery. The catheters are inserted under local or general anaesthesia, according to the wishes of the patient. The radiation source is then loaded into them to deliver a highly concentrated dose to the precise region of the excised tumour the region most likely to develop a local recurrence of the cancer. Using APBI means that the major part of the healthy breast tissue does not receive radiation.

"In a group of 258 women who had had breast-conserving surgery, we found that, at a median follow-up time of just over ten years, the rate of local recurrence the cancer coming back in the same place was 5.9% in the APBI group and 5.1% in the group who received whole breast irradiation," says Professor Polgr. "There was no significant difference in overall survival, cancer-specific survival, and disease free survival between the two groups. However, the differences in cosmetic outcome were striking 81% in the APBI group had good-to-excellent results as opposed to 63% of those who received whole b
'/>"/>

Contact: Mary Rice
mary.rice@riceconseil.eu
European Society for Radiotherapy and Oncology (ESTRO)
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. FDA Appoints Highly Qualified Scientific Experts to Tobacco Products Scientific Advisory Committee
2. 15 years after ACL knee reconstruction, 84 percent of male patients still highly active, study says
3. Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15
4. Swedes think highly of the government -- but not of the royal family
5. Whole body MRI is highly accurate in the early detection of breast cancer metastases
6. New weapon against highly resistant microbes within grasp
7. Lead poisoning highly prevalent among school-aged children in Uganda
8. Help wanted: Highly cited researchers needed for high-ranking positions at research institutions
9. Highly targeted radiation technique minimizes side effects of prostate cancer treatment
10. Highly interactive training helps workers in dangerous jobs avoid deadly mistakes
11. New vaccine candidate shows strong potential to prevent highly contagious norovirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Imprivata ® (NYSE: IMPR), ... secure communications solutions for the healthcare industry, today ... most widely selected single sign-on (SSO) solution amongst ... medical records (EMR) systems with a 51 percent ... in the last 12 months), according to HIMSS ...
(Date:7/30/2014)... obese people have a genetic mutation that seems to ... they see food, researchers report. Gaining a better ... and gratification at the sight of high-calorie foods like ... the scientists suggested. More than one-third of U.S. ... a combination of overeating, a lack of physical activity ...
(Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... As the controversy surrounding the use ... continues to grow, Bernstein Liebhard LLP notes that another ... a ban on uterine morcellation. According to a report ... leiomyosarcoma following a hysterectomy that involved the use of ... the aggressive cancer had progressed to Stage 4. Ms. ...
Breaking Medicine News(10 mins):Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... guidelines show half to two-thirds of women of childbearing ... News) -- A new study says federal guidelines on ... the category of "obese." , U.S. guidelines determine who ... whether a person,s height and weight are proportional. The ...
... much control a person has over their own health outcomes. ... when doctor and patient attitudes on the issue match up, ... Published online and in the May issue of the ... of a growing body of evidence indicating that patient-physician compatibility ...
... fewer side effects, experts say, , WEDNESDAY, April 21 (HealthDay ... promise in early testing as a possible new treatment for ... It,s too early to tell if the drug actually works, ... federal approval to be prescribed to patients. Still, the drug ...
... power, according to Penn State researchers who will test ... to help them manage their disease. The project, ... Chris Sciamanna, professor, department of medicine, Penn State College ... Lung and Blood Institute as part of the National ...
... ... , ... (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , a leader in safety ... Emeritus Professor of Surgery at Keck School of Medicine, University of Southern California. Dr. ...
... D.C. Women who have a breast density of 75 ... breast cancer that is four to five times greater than ... breast density one of the strongest biomarkers of breast cancer ... 101st Annual Meeting 2010, held in Washington, D.C., April 17-21, ...
Cached Medicine News:Health News:More U.S. Women May Be Obese Than Thought 2Health News:Patient-physician compatibility increases odds of following doctor's orders 2Health News:Patient-physician compatibility increases odds of following doctor's orders 3Health News:In Early Test, New Hepatitis C Drug Shows Promise 2Health News:Knowledge is power in Penn State blood pressure study 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3Health News:Mammographic density and risk of breast cancer 2Health News:Mammographic density and risk of breast cancer 3Health News:Mammographic density and risk of breast cancer 4Health News:Mammographic density and risk of breast cancer 5
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
(Date:7/30/2014)... 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), ... the cannabis testing and education markets, announced today that ... affairs not previously disclosed or, to its knowledge, any ... action. "We have noticed unusual price and ... trading days," said Steve Barbee , CEO of ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), ... and gastroenterology markets, today announced that it has entered ... a new Phase II development product. The Company has ... Injection and is evaluating the product for the treatment ...
... Inc. (NYSE: CRY ), an implantable biological ... that 2011 first quarter financial results will be released ... Company will hold a teleconference call and live webcast ... followed by a question and answer session hosted by ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results 2
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Medicine Products: